Quick Answer
AGIOS PHARMACEUTICALS, INC. reported R&D Expense of $339.54 million for fiscal year 2025.
AGIOS PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $339.54M | +12.7% |
| 2024 | $301.29M | +1.9% |
| 2023 | $295.53M | +5.6% |
| 2022 | $279.91M | +8.9% |
| 2021 | $256.97M | +16.4% |
| 2020 | $220.81M | +3.1% |
| 2019 | $214.26M | -37.2% |
| 2018 | $341.32M | +16.6% |
| 2017 | $292.68M | +32.9% |
| 2016 | $220.16M | +55.2% |
| 2015 | $141.83M | +41.3% |
| 2014 | $100.37M | +84.2% |
| 2013 | $54.50M | +32.8% |
| 2012 | $41.04M | +31.3% |
| 2011 | $31.25M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $86.80M | +19.8% | -5.6% |
| June 30, 2025 | $91.94M | +18.8% | +26.4% |
| March 31, 2025 | $72.74M | +6.0% | +0.4% |
| September 30, 2024 | $72.45M | -11.5% | -6.4% |
| June 30, 2024 | $77.40M | +12.3% | +12.8% |
| March 31, 2024 | $68.62M | +2.0% | -16.2% |
| September 30, 2023 | $81.84M | +26.0% | +18.8% |
| June 30, 2023 | $68.89M | -7.6% | +2.4% |
- AGIOS PHARMACEUTICALS, INC. showed an increase of +12.7% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, AGIOS PHARMACEUTICALS, INC.’s r&d expense has grown by 986.4% (from $31.25 million to $339.54 million).
- The most recent figure is from AGIOS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: